Novel pharmacological agents in clinical development for solid tumours

Author： Dy Grace K   Haluska Paul   Adjei Alex A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.12, 2001-12, pp. : 2059-2088

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours

By Scott Edwina N   Meinhardt Gerold   Jacques Christian   Laurent Dirk   Thomas Anne L  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 367-379

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological agents in development for invasive aspergillosis

By Meis Jaques FGM   Ruijgrok Elisabeth J  

Expert Opinion on Emerging Drugs, Vol. 7, Iss. 1, 2002-05 ,pp. : 33-45

Informa Healthcare

Access to resources Recommend Favorite

Biologic Aspects of Thrombopoietin and the Development of Novel Thrombopoietic Agents for Clinical Use

By  

Current Drug Discovery Technologies, Vol. 4, Iss. 3, 2007-10 ,pp. : 162-173

Bentham Science Publishers

Access to resources Recommend Favorite

Vinflunine, a Second Generation Novel Vinca Alkaloid with a Distinctive Pharmacological Profile, now in Clinical Development and Prospects for Future Mitotic Blockers

By  

Current Pharmaceutical Design, Vol. 7, Iss. 13, 2001-09 ,pp. : 1199-1212

Bentham Science Publishers

Access to resources Recommend Favorite

Development of pharmacological agents for targeting neurotrophins and their receptors

By Saragovi H.U.H.U.   Gehring K.K.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 3, 2000-03 ,pp. : 93-98

Elsevier

Access to resources Recommend Favorite